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Editorial on the Research Topic
Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response
The Research Topic “Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess
Clinical Response” includes eight papers with more than 50 authors contributing as experts in the
field. The Research Topic has the aim to reflect the state of the art on this emerging technology,
which is revolutionizing the clinical approach in oncology.
Despite the numerous progresses in early diagnosis and in target therapies, cancer remains the
second leading cause of death worldwide. Tumor molecular characterization plays a key role in
choosing the right treatment among the armamentarium available to the oncologist. Unfortunately,
with the traditional tissue biopsy in some cases analysis of tumor is not feasible due to insufficient or
poor quality material (Siravegna et al., 2019). Liquid biopsy has started to be considered a new
standard of care for oncological patients mainly after the FDA approval on 2016 of the first blood-
based test, to detect EGFR mutations for selecting patients who may benefit from the target therapy
(Torres et al, 2020). Indeed, liquid biopsy has several advantages, including its minimal invasiveness
and highly repeatability over the time, which potentially guarantees a dynamic picture of the tumor
and the chance to monitor pharmacological responses. This last characteristic makes liquid biopsy
particularly attractive within the oncological context. Indeed, to date, diagnosis and clinical
monitoring have been the two major applications of liquid biopsy, and are well described in our
Research Topic.
Kamatham et al., who used circulating tumor DNA (ctDNA) to identify, microsatellite instability
status in a pancreatic cancer patient. This led to switch the therapy from chemo to immuno-therapy,
with an excellent response. A different case report is presented by Nagaya et al., which uses
circulating tumor cell (CTC) analysis to select the right treatment in castration-resistant prostate
cancer (CRPC) patients. In this article, the authors evaluated AR-V7 expression in CTC in serial
blood tests; based on the results, abiraterone was selected as re-challenge in the setting of post-
chemo androgen-targeted-therapy.
Another example of a clinical application of liquid biopsy is presented by Dalle Fratte et al., present
a case report of a patient with KIT/PDGFRA wild-type gastrointestinal stromal tumor (GIST). The
patient was resistant to the standard treatment imatinib, even after increasing the dose. By using anin.org October 2020 | Volume 11 | Article 5982611
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(cfDNA) to investigate somatic changes responsible for imatinib
resistance, and identified a sharp increase in the allele
frequency of a TP53 mutation, responsible for a protein loss of
function, never described before. The same TP53 mutation was
retrospectively identified in the primary tumor and in the
metastatic hepatic lesion, suggesting a rapid clonal selection of
the mutation during tumor progression. Besides these case reports,
that highlight the potential of liquid biopsy in different cancer
types with no previous clinical indications, two contributions
describe the application of liquid biopsy in a high number of
patients. Buderath et al. evaluated levels of soluble PD-L1 and PD-
L2 in sera of 83 primary epithelial ovarian cancer (EOC) patients
and related the results with the presence of CTCs, clinical
characteristics and with PFS and OS. The results showed that
sPD-L1 and sPD-L2 could be used as complementary biomarkers
reflecting clinical status, treatment response and disease outcome
of EOC patients. In particular, sPD-L1 may facilitate the
identification of high-risk patients with unfavorable disease
outcomes despite platinum-sensitivity arguing for additional
therapeutic approaches. Pazdirek et al. investigated the potential
of ctDNA as blood-based biomarker in patients with locally
advanced rectal cancer (LARC) undergoing neoadjuvant
chemoradiotherapy (NCRT) prior to surgery. The study included
36 LARC patients undergoing NCRT followed by surgical
treatment. Somatic mutations were characterized in tissue
biopsies and ctDNA from plasma samples prior to therapy and at
the end of the first week of treatment (plasma only). The
analysis revealed a ctDNA reduction within the 1st week of
therapy, not associated with the clinical response determined.
The rapid ctDNA disappearance, unrelated with the therapy
outcome, suggests the need for further studies to better
understand its clinical significance in LARC patients within the
neoadjuvant setting.
Finally, three reviews illustrate the state of the art about the
scientific progress in liquid biopsy in different cancer types,
highlighting novel aspects. Cavallari et al. provide a critical
summary on the potential applications and its pitfalls of
circulating molecules in Malignant Pleural Mesothelioma
(MPM), an aggressive tumor linked to asbestos exposure. This
is often diagnosed at an advanced stage with consequent poor
prognosis. MPM diagnosis relies on pleural biopsies, therefore,
the development of circulating biomarkers for early diagnosis isFrontiers in Pharmacology | www.frontiersin.org 2of great importance. In particular, the identification of robust
non-invasive tests for the screening and risk assessment of
asbestos-exposed subjects is still an important unmet clinical
need. In this context, the authors reviewed the recent literature
with the aim to identify novel blood-based circulating
biomarkers for the early diagnosis and prognostic stratification
of MPM patients. Despite some other interesting potential
biomarkers, including miRNAs, CTCs, and ctDNA, validation
in large prospective studies is still awaited.
Chennakrishnaiah et al. focus their attention on the so-
called leukobiopsy. Recently, it has been reported that white
blood cells (WBCs) may represent a sort of reservoir of
circulating oncogenic DNA. Indeed, circulating WBCs, especially
neutrophils, may contain high levels of oncogenic DNA, exceeding
the amount of normally recovered fromsoluble fractions of plasma,
circulating extracellular vesicles, platelets, and others. In some
settings, the WBC content of cancer specific DNA (csDNA) may
represent an important source of csDNA contained in serum or in
plasma. Another thrilling topic is presented by Tieng et al., who
describes the importance of CTC single-cell transcriptomics
analyses in colorectal cancer (CRC). Single-cell RNA sequencing
(scRNA-seq) is emerging as a breakthrough technology which
provides the potential to dissect the different cellular populations
of cancers and possibly the intra tumor heterogeneity (ITH).
An important point raised by the authors is the role of
CTC in CRC metastasis and their characterization through
scRNA-seq.
In conclusion, the “Liquid Biopsy as a Tool for Precision
Oncology: New Challenges to Assess Clinical Response”
Research Topic highlights the importance of circulating
molecules as a new tool to achieve personalized therapy. In the
last decade, many progresses have been done, but at the same
time, many clinical aspects remain to be elucidated. In this
context, the papers enclosed in this topic offer the chance to
generate a collaborative discussion, contributing to the future
direction of liquid biopsy.AUTHOR CONTRIBUTIONS
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